368
References
- Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol.
2000;18(4 Suppl 20):S9–11. - Proven A, Gabriel SE, O’Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythro-
cyte sedimentation rate at diagnosis. J Rheumatol. 1999;26(6):1333–7. - Gamez-Nava JI, Gonzalez-Lopez L, Davis P, Suarez-Almazor ME. Referral and diagnosis of
common rheumatic diseases by primary care physicians. Br J Rheumatol. 1998;
37(11):1215–9. - Narvaez J, Nolla-Sole JM, Clavaguera MT, Valverde-Garcia J, Roig-Escofet D. Longterm
therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol.
1999;26(9):1945–52. - Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG. Adverse outcomes of antiin-
fl ammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum.
1997;40(10):1873–8. - Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, Hollywood J, Hutchings
A, Kyle V, Nott J, et al. BSR and BHPR guidelines for the management of polymyalgia rheu-
matica. Rheumatology (Oxford). 2010;49(1):186–90. - Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C,
Bachta A, Dejaco C, Duftner C, Slott Jensen H, et al. Patient-reported outcomes in polymyal-
gia rheumatica. J Rheumatol. 2012;39(4):795–803. - Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R, Morris M, Pease CT, Sherman
JW, Simon LS, et al. Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT
11: outcomes of importance for patients with PMR. J Rheumatol. 2014;41(4):819–23. - Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, Maradit-Kremers
H, Hutchings A, Matteson EL, Schirmer M, et al. Defi nition of remission and relapse in poly-
myalgia rheumatica: data from a literature search compared with a Delphi-based expert con-
sensus. Ann Rheum Dis. 2011;70(3):447–53. - Huang A, Castrejon I: Patient-reported outcomes in trials of patients with polymyalgia rheu-
matica: a systematic literature review. Rheumatology international 2016. Jan 14. [Epub ahead
of print]. - Lund B, Egsmose C, Jorgensen S, Krogsgaard MR. Establishment of the relative antiinfl am-
matory potency of defl azacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int.
1987;41(6):316–20. - Di Munno O, Beghe F, Favini P, Di Giuseppe P, Pontrandolfo A, Occhipinti G, Pasero
G. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and
calcium. Clin Rheumatol. 1989;8(2):202–7. - Di Munno O, Imbimbo B, Mazzantini M, Milani S, Occhipinti G, Pasero G. Defl azacort versus
methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinfl am-
matory potency of different treatment regimens. J Rheumatol. 1995;22(8):1492–8. - Krogsgaard MR, Lund B, Johnsson B. A long term prospective study of the equipotency
between defl azacort and prednisolone in the treatment of patients with polymyalgia rheumat-
ica. J Rheumatol. 1995;22(9):1660–2. - Salvarani C, Cantini F, Olivieri I, Barozzi L, Macchioni L, Boiardi L, Niccoli L, Padula A,
Pulsatelli L, Meliconi R. Corticosteroid injections in polymyalgia rheumatica: a double-blind,
prospective, randomized, placebo controlled study. J Rheumatol. 2000;27(6):1470–6. - Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled
trial. Arthritis Res Ther. 2010;12(5):R176. - Cimmino MA, Parodi M, Caporali R, Montecucco C. Is the course of steroid-treated polymy-
algia rheumatica more severe in women? Ann N Y Acad Sci. 2006;1069:315–21. - Calvo L, Pistone G, Arnone S, Colomba D, Amico S, Giacalone A, Vitale P, Nicosia C, Barone
E, Scaglione R, et al. Polymyalgia rheumatica and vertebral fractures: a 1-year pilot controlled
study. Rheumatol Int. 2010;30(9):1245–7.
I. Castrejon